FLT3 and acute myeloid leukemia: Notably, midostaurin has been the first inhibitor approved as front-line therapy in combination with intensive chemotherapy, showing high response rates with prolonged OS [13,14], and has become the current standard-of-care therapy to treat fit, newly diagnosed FLT3-mutated AML patients.